NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRYPTYR (acoltremon) is an ophthalmic solution approved by the FDA on May 28, 2025, for eye drop administration. The specific mechanism of action and therapeutic indications are not yet publicly detailed in available data. This product represents Alcon's entry into a specialized ophthalmic market segment.
Growth16.4 years to LOE
Early-stage commercial asset in growth phase with limited competitive pressure; brand and commercial teams are likely expanding.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRYPTYR represents an early-stage commercial opportunity within Alcon's ophthalmic portfolio during growth phase. Professionals joining this product can expect roles focused on market penetration, payer negotiations, and field sales expansion with minimal competitive disruption.
Brand ManagerField Sales Representative
Worked on TRYPTYR at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.